Overview

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A prospective, single-center Ia/Ib clinical study divided into two parts, including Phase Ia Dose Exploration and Phase Phase Ib Extension Phase.
Phase:
PHASE1
Details
Lead Sponsor:
Yizhuo Zhang
Treatments:
irinotecan sucrosofate
Temozolomide
Vincristine